The purpose of this clinical trial is to learn about the safety and effects of the study vaccine for the potential prevention of influenza. The study vaccine is called Self-Amplifying Ribonucleic Acid vaccine (saRNA vaccine). This study is seeking participants who: * Are between the age of 18 to 49 years old. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Are healthy as determined by medical history, physical examinations, and the study doctor. * For male participants, can father children and willing to use an acceptable method of contraception. Female participants who are not of childbearing potential; or male participant not able to father children. * Are capable of giving signed informed consent. Participants will receive either the saRNA vaccine, a licensed Influenza Vaccine (QIV) or a placebo. Participants will not know which vaccine they receive in advance. A placebo does not have any medicine in it but looks just like the study medicine. Participants will receive the study vaccines as a single shot in the arm. We will compare participant experiences to help us determine if the saRNA vaccine is safe and effective. Participants will take part in this study for 6 months. During this time, they will receive the study vaccine and participate in follow-up visits.
Age range
18 Years – 49 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of participants reporting local reactions
Timeframe: For 10 days after vaccination
Percentage of participants reporting systemic events
Timeframe: For 10 days after vaccination
Percentage of participants reporting adverse events
Timeframe: From vaccination to 4 weeks after vaccination
Percentage of participants reporting serious adverse events
Timeframe: From vaccination to 6 months after vaccination
Percentage of participants with abnormal hematology and chemistry laboratory values
Timeframe: 2 days after vaccination
Percentage of participants with abnormal hematology and chemistry laboratory values
Timeframe: 1 week after vaccination
Percentage of participants with grading shifts in hematology and chemistry laboratory assessments
Timeframe: Between baseline and 2 days after vaccination
Percentage of participants with grading shifts in hematology and chemistry laboratory assessments
Timeframe: Between baseline and 1 week after vaccination
Percentage of participants with new electrocardiogram (ECG) abnormalities
Timeframe: 2 days after vaccination
Percentage of participants with new ECG abnormalities
Timeframe: 1 week after vaccination